(Q50997374)

26 March 2018

title

Trends in C-reactive protein levels in US adults from 1999 to 2010. (English)

1 reference

26 March 2018

author

Kwok Leung Ong

1

1 reference

26 March 2018

Matthew A. Allison

2

1 reference

26 March 2018

Ben J Wu

object named as

Ben J Wu

4

0 references

Bernard M Y Cheung

3

object named as

Bernard M Y Cheung

1 reference

26 March 2018

author name string

Philip J Barter

5

1 reference

26 March 2018

Kerry-Anne Rye

6

1 reference

26 March 2018

language of work or name

English

0 references

publication date

12 May 2013

1 reference

26 March 2018

American Journal of Epidemiology

published in

1 reference

26 March 2018

volume

177

1 reference

26 March 2018

issue

12

1 reference

26 March 2018

page(s)

1430-1442

1 reference

26 March 2018

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

cites work

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

Evaluation of the combined use of adiponectin and C-reactive protein levels as biomarkers for predicting the deterioration in glycaemia after a median of 5.4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: results from the MONICA/KORA Augsburg Cohort Study, 1984-1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

High-sensitive C-reactive protein: universal prognostic and causative biomarker in heart disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

Association of lower total bilirubin level with statin usage: the United States National Health and Nutrition Examination Survey 1999-2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

Assessing kidney function--measured and estimated glomerular filtration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

Standards of medical care in diabetes--2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

Is glycemic control improving in U.S. adults?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

Utilization of lipid lowering medications among adults in the United States 1999-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

Serum Bilirubin and Genes Controlling Bilirubin Concentrations as Biomarkers for Cardiovascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

Serum bilirubin levels in familial hypercholesterolemia: a new risk marker for cardiovascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWS443

21 January 2018

Identifiers

DOI

10.1093/AJE/KWS443

1 reference

26 March 2018

1 reference

26 March 2018